Last reviewed · How we verify

LHRHA or Surgical Castration

University of Sydney · Phase 3 active Small molecule

LHRHA or Surgical Castration is a LHRH agonist / Surgical intervention Small molecule drug developed by University of Sydney. It is currently in Phase 3 development for Metastatic prostate cancer, Locally advanced prostate cancer.

LHRH agonists suppress testosterone production by desensitizing the pituitary gland, while surgical castration directly removes the testes to eliminate androgen production.

LHRH agonists suppress testosterone production by desensitizing the pituitary gland, while surgical castration directly removes the testes to eliminate androgen production. Used for Metastatic prostate cancer, Locally advanced prostate cancer.

At a glance

Generic nameLHRHA or Surgical Castration
SponsorUniversity of Sydney
Drug classLHRH agonist / Surgical intervention
TargetLHRH receptor (for LHRH agonist component)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

LHRH (luteinizing hormone-releasing hormone) agonists work by initially stimulating, then downregulating LHRH receptors on pituitary gonadotroph cells, ultimately suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, which leads to decreased testicular testosterone production. Surgical castration achieves androgen deprivation through direct removal of the testes, the primary source of testosterone. Both approaches achieve similar clinical endpoints of severe testosterone suppression for androgen-dependent diseases.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about LHRHA or Surgical Castration

What is LHRHA or Surgical Castration?

LHRHA or Surgical Castration is a LHRH agonist / Surgical intervention drug developed by University of Sydney, indicated for Metastatic prostate cancer, Locally advanced prostate cancer.

How does LHRHA or Surgical Castration work?

LHRH agonists suppress testosterone production by desensitizing the pituitary gland, while surgical castration directly removes the testes to eliminate androgen production.

What is LHRHA or Surgical Castration used for?

LHRHA or Surgical Castration is indicated for Metastatic prostate cancer, Locally advanced prostate cancer.

Who makes LHRHA or Surgical Castration?

LHRHA or Surgical Castration is developed by University of Sydney (see full University of Sydney pipeline at /company/university-of-sydney).

What drug class is LHRHA or Surgical Castration in?

LHRHA or Surgical Castration belongs to the LHRH agonist / Surgical intervention class. See all LHRH agonist / Surgical intervention drugs at /class/lhrh-agonist-surgical-intervention.

What development phase is LHRHA or Surgical Castration in?

LHRHA or Surgical Castration is in Phase 3.

What are the side effects of LHRHA or Surgical Castration?

Common side effects of LHRHA or Surgical Castration include Hot flashes, Erectile dysfunction, Decreased libido, Gynecomastia, Fatigue, Bone density loss / osteoporosis.

What does LHRHA or Surgical Castration target?

LHRHA or Surgical Castration targets LHRH receptor (for LHRH agonist component) and is a LHRH agonist / Surgical intervention.

Related